Aerogen today touted results from a study showing a 32% reduction in hospital admissions when patients were treated using its Solo vibrating mesh aerosol drug delivery system, compared to a small-volume nebulizer.
The Chicago-based company’s vibrating mesh is used to treat respiratory disorders such as COPD, asthma, or influenza, all of which are exacerbated in the winter season. The study’s results were presented at the American Assn. of Respiratory Care in San Antonio and the American College of Emergency Physicians in Las Vegas.
Get the full story at our sister site, Drug Delivery Business News.
The post Aerogen touts study of Solo vibrating mesh for aerosol drug delivery appeared first on MassDevice.
from MassDevice http://ift.tt/2dJb7ci
Cap comentari:
Publica un comentari a l'entrada